Fig. 3. Stimulation of GαsDREADD in DLS dMSNs does not activate Fyn/GluN2B signaling.

a The DLS of D1-Cre mice was infected bilaterally with AAV-DIO-rM3D(Gs)-mCherry (10¹³ vg/ml, 1 μl per side), and infection was evaluated 4 weeks later. Infection was visualized on EVOS FL microscope (Life Technologies, Carlsbad, CA), scale: 2×. b Timeline of experiment. Four weeks after surgery, vehicle (0.5% DMSO) or CNO (3 mg/kg) was systemically administered, and the DLS was dissected 30 min later. c Representative image of Fyn activation and GluN2B phosphorylation using anti-Tyr418/420[Src/Fyn] and anti-Tyr1472[GluN2B] antibodies, respectively. Total protein levels of Fyn, GluN2B and actin, which was used as a loading control, were measured in parallel. d, e Data are presented as the individual data points and mean densitometry values of the phosphorylated protein divided by the densitometry values of the total protein ± SEM and expressed as % of vehicle. Activation of GαsDREADD in DLS dMSNs does not change Fyn activation (d) (two-tailed unpaired t-test, t = 0.2957, p = 0.7742) and GluN2B phosphorylation (e) (two-tailed unpaired t-test, t = 0.4105, p = 0.6910). n = 5–6 per treatment. ns non-significant.